<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03378076</url>
  </required_header>
  <id_info>
    <org_study_id>FX006-2017-012</org_study_id>
    <nct_id>NCT03378076</nct_id>
  </id_info>
  <brief_title>Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA</brief_title>
  <official_title>A Randomized, Open-label, Parallel Group Study in Patients With Bilateral Knee Osteoarthritis Comparing the Systemic Exposure of Triamcinolone Acetonide Following Administration Into Both Knees of Either Extended-release FX006 or Immediate-release TAcs (Triamcinolone Acetonide Suspension)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Flexion Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Flexion Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, parallel group study to compare systemic exposure of
      triamcinolone acetonide following administration into both knees of either FX006 or TAcs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open label, parallel group study that will be conducted in male and
      female patients ≥ 40 years of age with bilateral knee OA.

      Approximately 24 patients will be randomized to one of two treatment groups (1:1) and treated
      with IA injections to both knees of either:

        -  extended-release FX006 64 mg total dose (approximately 12 patients) or

        -  immediate-release TAcs 80 mg total dose (approximately 12 patients) Each patient will be
           screened to confirm the diagnosis of OA and eligibility based on the inclusion/exclusion
           requirements and will be randomized to treatment on Day 1. Following screening,
           pharmacokinetics (PK) and safety will be evaluated at 6 out-patient visits scheduled on
           Study Days 1 [calendar day of injection], 2, 8, 15, 29, and 43.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 6, 2017</start_date>
  <completion_date type="Actual">March 14, 2018</completion_date>
  <primary_completion_date type="Actual">March 14, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure the Concentration of Triamcinolone Acetonide (TA) in Blood Plasma</measure>
    <time_frame>43 days</time_frame>
    <description>Plasma drug concentrations (pg/mL) by Time Point across FX006 and TAcs treatment arms in plasma.
For the PK analysis and individual concentration vs. time plots, a concentration that is BLOQ is assigned a value of zero if it occurs in a profile before the first measurable concentration. If a BLOQ value occurs after a measurable concentration in a profile and is followed by a value above the lower limit of quantification, then the BLOQ is treated as missing data. If a BLOQ value occurs at the end of the collection interval (after the last quantifiable concentration) it is set to zero. If two BLOQ values occur in succession after Cmax, the profile is deemed to have terminated at the first BLOQ value and any subsequent concentrations are set to zero for PK calculations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events</measure>
    <time_frame>43 days</time_frame>
    <description>Safety analyses were conducted using the safety population.
Analyses of adverse events will be performed for those events that are considered treatment emergent, where treatment emergent is defined as any adverse event with onset after the administration of study medication in the first knee through the end of the study or any event that was present at baseline but worsened in intensity through the end of the study. Severity of Adverse events were graded by the Principal Investigator using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The grading went from Grade 1 (Mild) to Grade 5 (Death related to AE).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Bilateral Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>FX006 32 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two intra-articular (IA) injections of FX006 32 mg (total dose of 64 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAcs 40 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two intra-articular (IA) injections of TAcs 40 mg (total dose of 80 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FX006 32 mg</intervention_name>
    <description>Drug: Extended-release 32 mg FX006 IA injection into each knee (total 64 mg dose)</description>
    <arm_group_label>FX006 32 mg</arm_group_label>
    <other_name>Zilretta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAcs 40 mg</intervention_name>
    <description>Drug: Immediate-release 40mg TAcs IA injection into each knee (total 80 mg dose)</description>
    <arm_group_label>TAcs 40 mg</arm_group_label>
    <other_name>Kenalog®-40 Injection</other_name>
    <other_name>Triamcinolone Acetonide Crystalline Suspension (TAcs)</other_name>
    <other_name>TCA-IR 40</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written consent to participate in the study

          -  Male or female greater than or equal to 40 years of age

          -  Symptoms consistent with OA in both knees for greater than or equal to 6 months prior
             to Screening (patient reported is acceptable)

          -  Currently meets ACR Criteria (clinical and radiological) for OA in both knees

          -  Knee pain in both knees for greater than 15 days over the last month (as reported by
             the patient)

          -  Body mass index (BMI) less than or equal to 40 kg/m2

          -  Morning serum cortisol result within normal range at Screening (5-23 mcg/dL or 138-635
             nmol/dL)

          -  Ambulatory and in good general health

          -  Willing and able to comply with the study procedures and visit schedules and able to
             follow verbal and written instructions.

          -  Willing to abstain from use of protocol-restricted medications during the study

        Exclusion Criteria:

          -  Reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis,
             or arthritis associated with inflammatory bowel disease

          -  History of infection in either knee joint

          -  Clinical signs and symptoms of active knee infection or crystal disease in either knee
             within 1 month of Screening

          -  Unstable joint (such as a torn anterior cruciate ligament) in either knee within 12
             months of Screening

          -  Presence of surgical hardware or other foreign body in either knee

          -  Surgery or arthroscopy of either knee within 12 months of Screening

          -  IA treatment of any joint with any of the following agents within six (6) months of
             Screening: any corticosteroid preparation (investigational or marketed, including
             FX006), any biologic agent (e.g., platelet rich plasma (PRP) injection, stem cells,
             prolotherapy, amniotic fluid injection; investigational or marketed).

          -  IA treatment in either knee with hyaluronic acid (investigational or marketed) within
             6 months of Screening

          -  Parenteral or oral corticosteroids (investigational or marketed) within 3 months of
             Screening

          -  Inhaled, intranasal or topical corticosteroids (investigational or marketed) within 2
             weeks of Screening

          -  Females who are pregnant or nursing or plan to become pregnant during the study; men
             who plan to conceive during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Kelley, MD</last_name>
    <role>Study Director</role>
    <affiliation>Flexion Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LA Biomed at Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>December 8, 2017</study_first_submitted>
  <study_first_submitted_qc>December 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2017</study_first_posted>
  <results_first_submitted>March 4, 2019</results_first_submitted>
  <results_first_submitted_qc>April 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 1, 2019</results_first_posted>
  <last_update_submitted>November 20, 2019</last_update_submitted>
  <last_update_submitted_qc>November 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Knee</keyword>
  <keyword>Corticosteroid</keyword>
  <keyword>Bilateral</keyword>
  <keyword>Pain</keyword>
  <keyword>Intra-articular</keyword>
  <keyword>Injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 10, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT03378076/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT03378076/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>FX006 32 mg</title>
          <description>12 subjects received FX006 32 mg as a single 5 mL IA injection into each knee for a total of total 64 mg dose</description>
        </group>
        <group group_id="P2">
          <title>TAcs IR 40 mg</title>
          <description>12 subjects received TAcs 40 mg as a single 5 mL IA injection into each knee for a total 80 mg dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FX006 64 mg</title>
          <description>Single 5 mL IA injection into each knee</description>
        </group>
        <group group_id="B2">
          <title>TAcs IR 80mg</title>
          <description>Single 5 mL IA injection into each knee</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.8" spread="6.45"/>
                    <measurement group_id="B2" value="61.6" spread="8.17"/>
                    <measurement group_id="B3" value="61.7" spread="7.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.31" spread="3.669"/>
                    <measurement group_id="B2" value="30.35" spread="4.955"/>
                    <measurement group_id="B3" value="31.83" spread="4.524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measure the Concentration of Triamcinolone Acetonide (TA) in Blood Plasma</title>
        <description>Plasma drug concentrations (pg/mL) by Time Point across FX006 and TAcs treatment arms in plasma.
For the PK analysis and individual concentration vs. time plots, a concentration that is BLOQ is assigned a value of zero if it occurs in a profile before the first measurable concentration. If a BLOQ value occurs after a measurable concentration in a profile and is followed by a value above the lower limit of quantification, then the BLOQ is treated as missing data. If a BLOQ value occurs at the end of the collection interval (after the last quantifiable concentration) it is set to zero. If two BLOQ values occur in succession after Cmax, the profile is deemed to have terminated at the first BLOQ value and any subsequent concentrations are set to zero for PK calculations</description>
        <time_frame>43 days</time_frame>
        <population>All patients who received 2 IA injections (one in each knee) of study drug, completed scheduled sampling, and had sufficient plasma concentration data</population>
        <group_list>
          <group group_id="O1">
            <title>FX006 32 mg</title>
            <description>Two 5 mL IA injections (total dose of 64 mg)</description>
          </group>
          <group group_id="O2">
            <title>TAcs 40 mg</title>
            <description>Two 1mL IA injections (total dose of 80 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Measure the Concentration of Triamcinolone Acetonide (TA) in Blood Plasma</title>
          <description>Plasma drug concentrations (pg/mL) by Time Point across FX006 and TAcs treatment arms in plasma.
For the PK analysis and individual concentration vs. time plots, a concentration that is BLOQ is assigned a value of zero if it occurs in a profile before the first measurable concentration. If a BLOQ value occurs after a measurable concentration in a profile and is followed by a value above the lower limit of quantification, then the BLOQ is treated as missing data. If a BLOQ value occurs at the end of the collection interval (after the last quantifiable concentration) it is set to zero. If two BLOQ values occur in succession after Cmax, the profile is deemed to have terminated at the first BLOQ value and any subsequent concentrations are set to zero for PK calculations</description>
          <population>All patients who received 2 IA injections (one in each knee) of study drug, completed scheduled sampling, and had sufficient plasma concentration data</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1- Hour 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1801.5" lower_limit="1261.50" upper_limit="2572.77"/>
                    <measurement group_id="O2" value="4507.9" lower_limit="1205.43" upper_limit="16857.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1893.6" lower_limit="1328.58" upper_limit="2698.84"/>
                    <measurement group_id="O2" value="5140.1" lower_limit="1327.67" upper_limit="19899.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - Hour 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1958.1" lower_limit="1336.54" upper_limit="2868.86"/>
                    <measurement group_id="O2" value="5443.8" lower_limit="1357.81" upper_limit="21825.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - Hour 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2013.8" lower_limit="1381.39" upper_limit="2935.59"/>
                    <measurement group_id="O2" value="5454.2" lower_limit="1409.98" upper_limit="21098.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - Hour 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1914.4" lower_limit="1291.93" upper_limit="2836.82"/>
                    <measurement group_id="O2" value="5338.9" lower_limit="1366.93" upper_limit="20852.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - Hour 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1900.2" lower_limit="1293.77" upper_limit="2790.96"/>
                    <measurement group_id="O2" value="5430.6" lower_limit="1442.24" upper_limit="20448.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1928.1" lower_limit="1288.45" upper_limit="2885.17"/>
                    <measurement group_id="O2" value="5199.0" lower_limit="1418.52" upper_limit="19054.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - Hour 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1839.8" lower_limit="1241.72" upper_limit="2725.96"/>
                    <measurement group_id="O2" value="4948.8" lower_limit="1392.07" upper_limit="17593.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - Hour 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1793.9" lower_limit="1247.06" upper_limit="2580.66"/>
                    <measurement group_id="O2" value="4507.8" lower_limit="1294.51" upper_limit="15697.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 - Hour 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1948.8" lower_limit="1349.93" upper_limit="2813.36"/>
                    <measurement group_id="O2" value="4185.4" lower_limit="1614.39" upper_limit="10850.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1397.0" lower_limit="1073.13" upper_limit="1818.65"/>
                    <measurement group_id="O2" value="450.8" lower_limit="230.66" upper_limit="880.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="956.2" lower_limit="759.23" upper_limit="1204.25"/>
                    <measurement group_id="O2" value="428.7" lower_limit="231.92" upper_limit="792.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="445.8" lower_limit="313.12" upper_limit="634.80"/>
                    <measurement group_id="O2" value="334.6" lower_limit="182.45" upper_limit="613.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265.8" lower_limit="199.56" upper_limit="354.03"/>
                    <measurement group_id="O2" value="241.0" lower_limit="119.11" upper_limit="487.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Treatment Emergent Adverse Events</title>
        <description>Safety analyses were conducted using the safety population.
Analyses of adverse events will be performed for those events that are considered treatment emergent, where treatment emergent is defined as any adverse event with onset after the administration of study medication in the first knee through the end of the study or any event that was present at baseline but worsened in intensity through the end of the study. Severity of Adverse events were graded by the Principal Investigator using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The grading went from Grade 1 (Mild) to Grade 5 (Death related to AE).</description>
        <time_frame>43 days</time_frame>
        <population>All patients who received study drug (injection in at least one knee).</population>
        <group_list>
          <group group_id="O1">
            <title>FX006 32 mg</title>
            <description>Two 5 mL IA injections (total dose of 64 mg)</description>
          </group>
          <group group_id="O2">
            <title>TAcs 40 mg</title>
            <description>Two 1mL IA injections (total dose of 80 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Treatment Emergent Adverse Events</title>
          <description>Safety analyses were conducted using the safety population.
Analyses of adverse events will be performed for those events that are considered treatment emergent, where treatment emergent is defined as any adverse event with onset after the administration of study medication in the first knee through the end of the study or any event that was present at baseline but worsened in intensity through the end of the study. Severity of Adverse events were graded by the Principal Investigator using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The grading went from Grade 1 (Mild) to Grade 5 (Death related to AE).</description>
          <population>All patients who received study drug (injection in at least one knee).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with TEAE Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with TEAE Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with TEAE Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with TEAE Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with TEAE Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected following IA administration through the final study visit at 43 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>FX006 32 mg</title>
          <description>Two 5 mL intra-articular injection
FX006: Sustained Release Steroid</description>
        </group>
        <group group_id="E2">
          <title>TAcs 40 mg</title>
          <description>Commercially available triamcinolone acetonide, two 1 mL intra-articular injection
TAcs: Immediate Release Steroid</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vessel Puncture Site Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food Allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>White Blood Cell Count Decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Joint Swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Scott Kelley, Chief Medical Officer</name_or_title>
      <organization>Flexion Therapeutics</organization>
      <phone>781-305-7142</phone>
      <email>skelley@flexiontherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

